Tilman S.A.

About Tilman S.A.

Tilman® is a Belgian pharmaceutical laboratory with 65 year of expertise in the development and production of registered medicines and food supplements from plant-based active ingredients. Tilman® innovates continuously to provide healthcare professionals with effective, reliable alternatives to traditional chemical drugs. It is renow...

Certifications
  • BE
  • 2022
    On CPHI since
  • 3
    Certificates
  • 250 - 499
    Employees
Company types
Manufacturer/Innovator
OTC
Pharmaceutical company
Primary activities
Nutraceuticals
OTC
Pharmaceutical Company (innovator finished products)
Contact info
Meet us at

CPHI Milan 2024

Fiera Milano, Italy
08 Oct 2024 - 10 Oct 2024

Products from Tilman S.A. (4)

  • Antimetil®

    Product Antimetil®

    One Antimetil® tablet contains 50 mg ginger extract standardized to 10% gingerol, equivalent to 500 mg ginger powder, and helps maintain digestive well-being. Use: to aid digestion in the event of overeating or before a heavy meal - during pregnancy and when traveling, 30 minutes before departure.The Antim...
  • Flexofytol® FORTE

    Product Flexofytol® FORTE

    Flexofytol® FORTE contributes to the flexibility of joints and tendons

    The most prescribed Curcumin in Belgium
    High rate of consumer satisfaction
    The only scientifically studied Curcumin with double-blind placebo-control in Belgium!
    Flexofytol® FORTE can be used for long periods with ...
  • Nasafytol® - NutraIngredients Awards WINNER -

    Product Nasafytol® - NutraIngredients Awards WINNER -

    Nasafytol® maintains the effectiveness of the IMMUNE DEFENCES.
    Supporting the immunity allows a better protection of the body against external aggressions. Nasafytol® maintains the health of the LUNGS and of the upper RESPIRATORY TRACT.
    Nasafytol® is scientifically studied.

  • Sedistress® 200

    Product Sedistress® 200

    STRESS, NERVOUSNESS, PROBLEMS FALLING ASLEEP
    Registered herbal medecine in Europe
    Sedistress® 200 is clinically proven with studies in > 3000 patients